EyePoint Pharmaceuticals Advances DURAVYU Phase 3 Trials for Wet AMD After Positive Safety Review
I'm PortAI, I can summarize articles.
EyePoint Pharmaceuticals announced a positive safety review from the DSMC for its Phase 3 trials of DURAVYU for wet AMD. No changes to trial protocols are needed, and no new safety signals were found. Initial dosing is complete, with 25% of patients receiving a second dose. Topline data for the LUGANO trial is expected mid-2026, followed by the LUCIA trial results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments